Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $7.19 on Wednesday. The stock’s 50-day moving average price is $6.28 and its two-hundred day moving average price is $6.96. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $27.39.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SAGE. Truist Financial reduced their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Piper Sandler cut their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Stifel Nicolaus cut their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Monday, December 16th. HC Wainwright restated a “neutral” rating and set a $14.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a research note on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.